Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2001
10/10/2001EP1140175A2 Antibodies to truncated vegf-d and uses thereof
10/10/2001EP1140173A2 Vascular endothelial cell growth factor antagonists and uses thereof
10/10/2001EP1140171A1 Methods and products for regulating lectin complement pathway associated complement activation
10/10/2001EP1140139A2 Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
10/10/2001EP1140138A2 Therapeutic applications of flint polypeptides
10/10/2001EP1140134A1 Agent for treating visual cell function disorder
10/10/2001EP1140119A1 Novel therapeutic application of low molecular weight heparin
10/10/2001EP1140115A2 Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents
10/10/2001EP1140113A2 Use of bisphosphonates for the prevention and treatment of infectious processes
10/10/2001EP1140107A1 Agonists and antagonists of peripheral-type benzodiazepine receptors
10/10/2001EP1140104A1 Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases
10/10/2001EP1140099A1 Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia
10/10/2001EP1140098A2 Tricyclic nitrogen heterocycles as pde iv inhibitors
10/10/2001EP1140096A1 Utilization of pyrimidine derivatives for preventing and treating cerebral ischaemia
10/10/2001EP1140095A1 (2-imidazoline-2-ylamino) quinoxaline derivatives for the treatment of pain
10/10/2001EP1140092A2 Method of treating sexual disturbances
10/10/2001EP1140083A1 Novel compounds
10/10/2001EP1140079A1 Assays for ligands for nuclear receptors
10/10/2001EP1140078A2 Benzimidazole vascular damaging agents
10/10/2001EP1140077A2 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
10/10/2001EP1140072A1 Compounds and methods
10/10/2001EP1140071A1 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
10/10/2001EP1140069A1 COMPOUNDS WHICH AFFECT mRNA STABILITY AND USES THEREFOR
10/10/2001EP1140065A1 Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease
10/10/2001EP1140054A2 Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
10/10/2001EP1140049A2 Compositions and methods to inactivate n-type calcium channels
10/10/2001EP1140045A2 Homer a new target of treating psychiatric disorders
10/10/2001EP1140038A1 Transdermal drug delivery system
10/10/2001EP1140030A2 Medicament forms having controlled release and containing active substances which easily dissolve in water
10/10/2001EP1140026A1 Biodegradble polymer encapsulated serotonin receptor antagonist and method for preparing the same
10/10/2001EP1140025A1 Granules for oral administration, process for producing the same, and tablets produced from the granules
10/10/2001EP1139913A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents
10/10/2001EP1139753A1 Formulations for treating disease and methods of using same
10/10/2001EP1139751A1 Efficient and stable $i(in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
10/10/2001EP1139744A1 Exo-r-mecamylamine formulation and use in treatment
10/10/2001EP1139743A1 Exo-s-mecamylamine formulation and use in treatment
10/10/2001EP1083172A4 N-substituted derivatives of 5-oxyiminobarbituric acid
10/10/2001EP0922044B1 Pyrrolo(3,2-c) quinoline derivatives
10/10/2001EP0840620B1 Il-8 antagonists for treatment of asthma
10/10/2001EP0830372B1 Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
10/10/2001EP0765320B1 Benzimidazolone derivatives with central dopaminergic activity
10/10/2001EP0764163B1 Tachykinin (nk 1) receptor antagonists
10/10/2001CN1317047A GBS toxin receptor
10/10/2001CN1317043A Polypeptides and polynucleotides from coagulase-negative staphylocoui
10/10/2001CN1317015A Human anti-factor IX/IXa antibodies
10/10/2001CN1317005A Substituted pyrazole derivatives condensed with six-membered heterocyclic rings
10/10/2001CN1316998A Thiobenzimidazole derivatives
10/10/2001CN1316995A Hydroxy 2-pipecolate hydroxamide acid derivatives as MMP inhititors
10/10/2001CN1316994A Piperidine derivatives
10/10/2001CN1316993A 4,4-biarylpiperidime derivatives with opioid receptor activity
10/10/2001CN1316992A Process for preparation of zofenopril calcium salt
10/10/2001CN1316991A Azetidine derivatives, preparation and medicines containing them
10/10/2001CN1316911A Compositions comprising sympathomimetic amine salts unsuitable for illegal use
10/10/2001CN1316902A Therapeutic compositions (II)
10/10/2001CN1316419A Arenesulfonyl amino-iso hydroximic acid derivative
10/10/2001CN1316259A Nuandi rhodobryum preparation and its preparing process
10/10/2001CN1072670C Trans-apovincaminic acid ester derivatives as drugs
10/10/2001CN1072663C Novel benzoyl guanidine derivatives, process for their preparation and thier use in the preparation of medicines
10/10/2001CN1072647C Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors
10/10/2001CN1072644C 4-fluoroalkyl substituted phenacyl guanidine, its prpearing method, application as medicine or diagnosis agent and medicine containing such compound
10/10/2001CN1072503C Medicine for treating angitis
10/10/2001CN1072502C Medicine for treating angitis
10/10/2001CN1072501C Pile-diminishing capsule
10/10/2001CN1072497C Medicine for curing hemiplegia and its making method
10/09/2001US6300499 α1-adrenergic receptor antagonists
10/09/2001US6300376 Indane dimer compounds and their pharmaceutical use
10/09/2001US6300366 Aminopyrroline compounds
10/09/2001US6300359 (E)-3-[1-n-Butyl-5-[2-(2-carboxyphenyl)methoxy-4-chlorophenyl]-1H-pyrazol-4-yl]-2-[(5-methoxy-2,3-dihydrobenzofuran-6-yl)methyl]-prop-2-enoic acid monoargininyl salt
10/09/2001US6300356 Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist
10/09/2001US6300344 Heterocyclic compounds
10/09/2001US6300334 Thieno[2,3-d]pyrimidine-2,4-diones
10/09/2001US6299925 Effervescent green tea extract formulation
10/09/2001US6299897 Attaching selectin binding carbohydrate to a cross-linkable lipid; attaching an acidic group to a cross linkable lipid; forming lipids into sheet; crosslinking lipids
10/09/2001CA2235025C Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis
10/09/2001CA2202057C 5-lipoxygenase inhibitors
10/09/2001CA2161297C Novel diosmetin derivatives; process for preparing the same and pharmaceutical_compositions containing them
10/09/2001CA2119662C New nitrogen bicyclic derivatives, their preparation process and pharmaceutical compositions comtaining them
10/09/2001CA1341301C Preparation of functional human urokinase proteins
10/07/2001CA2304906A1 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/05/2001CA2303481A1 Pharmaceutical compositions comprising moexipril magnesium
10/04/2001WO2001073034A2 Beta-like glycoprotein hormone polypeptide and heterodimer
10/04/2001WO2001073033A2 Anti-angiogenic and anti-tumor properties of matin and other laminin domains
10/04/2001WO2001073029A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
10/04/2001WO2001073025A2 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains
10/04/2001WO2001072960A2 Il-8 receptor antagonists
10/04/2001WO2001072839A2 Human g-protein coupled receptors
10/04/2001WO2001072836A2 G-protein coupled receptors
10/04/2001WO2001072835A1 Family of human sodium cation channels and use thereof
10/04/2001WO2001072831A2 Immunoregulator
10/04/2001WO2001072830A2 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction
10/04/2001WO2001072829A2 Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
10/04/2001WO2001072779A1 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
10/04/2001WO2001072778A2 Method of identifying inhibitors of tie-2
10/04/2001WO2001072777A2 Human transcription factors
10/04/2001WO2001072772A2 Calcium binding regulatory subunit
10/04/2001WO2001072762A1 Pharmaceutical compositions containing oligosaccharides and preparation thereof
10/04/2001WO2001072758A1 Tricyclic protein kinase inhibitors
10/04/2001WO2001072752A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS
10/04/2001WO2001072745A1 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders
10/04/2001WO2001072744A1 N-heterocyclic derivatives as nos inhibitors
1 ... 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 ... 1595